" /> Bevacizumab/Carboplatin/Docetaxel Regimen - CISMeF





Preferred Label : Bevacizumab/Carboplatin/Docetaxel Regimen;

NCIt synonyms : Avastin/Carboplatin/Docetaxel; Carboplatin/Bevacizumab/Docetaxel; Docetaxel/Carboplatin/Bevacizumab; Carboplatin/Docetaxel/Bevacizumab; Bevacizumab/Carboplatin/Docetaxel; Docetaxel/Bevacizumab/Carboplatin; Bevacizumab-Carboplatin-Docetaxel;

NCIt related terms : Carboplatin and Docetaxel (DCb) and Bevacizumab-adcd; Carboplatin and Docetaxel (DCb) and Bevacizumab; Carboplatin and Docetaxel (DCb) and Bevacizumab-awwb; Carboplatin and Docetaxel (DCb) and Bevacizumab-aybi; Carboplatin and Docetaxel (DCb) and Bevacizumab-bvzr; Carboplatin and Docetaxel (DCb) and Bevacizumab-tnjn; Carboplatin and Docetaxel (DCb) and Bevacizumab-equi; Carboplatin and Docetaxel (DCb) and Bevacizumab-maly; Carboplatin and Docetaxel (DCb) and Bevacizumab-onbe;

NCIt definition : A regimen consisting of bevacizumab, carboplatin and docetaxel that can be used in the treatment of non-small cell lung cancer (NSCLC).;

NCI Metathesaurus CUI : CL1913062;

Codes from synonyms : 296; 139836; 139835; 139839; 139838; 142159; 110541; 139841; 139840;

Details


You can consult :


Nous contacter.
02/08/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.